Diagnostic advances bode well for the imminent expansion of the global COVID-19 detection kits market, which is expected to be worth $8 billion by 2027.
The real-time bioaerosol sampling system can detect a very low concentration of SARS-CoV-2 in the air.
During a session at this week’s Consumer Electronics Show, Andrea Wainer, EVP of Rapid Molecular Diagnostics at Abbott, shares how the company scaled up to supply the global market with more than 300 million COVID-19 tests in 2020 and the path forward.
Diagnostic companies are hustling to increase availability of testing.
Researchers have developed a test that may be more sensitive that currently available lab tests.